[HTML][HTML] Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017

VN Giri, KE Knudsen, WK Kelly, W Abida… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this
conference was to develop an expert consensus-driven working framework for …

[HTML][HTML] Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data

LI Karsh, ET Gross, CM Pieczonka, PJ Aliotta… - Urology, 2018 - Elsevier
Objective To provide an update on SpaceOAR System, a Food and Drug Administration–
approved hydrogel indicated to create distance between the prostate and the rectum which …

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

SA Boorjian, M Alemozaffar, BR Konety… - The lancet …, 2021 - thelancet.com
Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder
cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient …

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

MR Smith, HI Scher, S Sandhu, E Efstathiou… - The Lancet …, 2022 - thelancet.com
Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

[HTML][HTML] Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer

T Zhang, LI Karsh, MJ Nissenblatt… - Clinical genitourinary …, 2020 - Elsevier
Many therapeutic options are now available for men with metastatic castration-resistant
prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted …

[HTML][HTML] Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell …

A Amin, AZ Dudek, TF Logan, RS Lance… - … for immunotherapy of …, 2015 - Springer
Background AGS-003 is an autologous immunotherapy prepared from fully matured and
optimized monocyte-derived dendritic cells, which are co-electroporated with amplified …

Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor …

EM Messing, CM Tangen, SP Lerner… - Jama, 2018 - jamanetwork.com
Importance Low-grade non–muscle-invasive urothelial cancer frequently recurs after
excision by transurethral resection of bladder tumor (TURBT). Objective To determine …

[HTML][HTML] Intravesical rAd–IFNα/Syn3 for patients with high-grade, Bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II …

ND Shore, SA Boorjian, DJ Canter, K Ogan… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are
either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease …

[HTML][HTML] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting

J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate cancer and …, 2018 - nature.com
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …

A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer

EJ Small, RS Lance, TA Gardner, LI Karsh, L Fong… - Clinical Cancer …, 2015 - AACR
Purpose: This phase II open-label study evaluated the effect of concurrent or sequential
administration of abiraterone acetate plus prednisone (AA+ P) on sipuleucel-T manufacture …